AU2023282347A1 - Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate - Google Patents

Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate Download PDF

Info

Publication number
AU2023282347A1
AU2023282347A1 AU2023282347A AU2023282347A AU2023282347A1 AU 2023282347 A1 AU2023282347 A1 AU 2023282347A1 AU 2023282347 A AU2023282347 A AU 2023282347A AU 2023282347 A AU2023282347 A AU 2023282347A AU 2023282347 A1 AU2023282347 A1 AU 2023282347A1
Authority
AU
Australia
Prior art keywords
methylene
citrate
tetrahydrofolic acid
lyophilized composition
disodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023282347A
Other languages
English (en)
Inventor
Thomas Ammann
Viola Groehn
Jean-Pierre KNAPP
Rudolf Moser
Marianne Svaerd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2023282347A1 publication Critical patent/AU2023282347A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023282347A 2022-06-08 2023-06-05 Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate Pending AU2023282347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22177932 2022-06-08
EP22177932.5 2022-06-08
PCT/EP2023/064972 WO2023237484A1 (en) 2022-06-08 2023-06-05 Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Publications (1)

Publication Number Publication Date
AU2023282347A1 true AU2023282347A1 (en) 2025-01-16

Family

ID=81984853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023282347A Pending AU2023282347A1 (en) 2022-06-08 2023-06-05 Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Country Status (9)

Country Link
US (1) US20250360135A1 (https=)
EP (2) EP4536187B1 (https=)
JP (1) JP2025518274A (https=)
KR (1) KR20250022145A (https=)
CN (1) CN119365186A (https=)
AU (1) AU2023282347A1 (https=)
CA (1) CA3258734A1 (https=)
IL (1) IL317395A (https=)
WO (1) WO2023237484A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1215945A (en) 1983-03-20 1986-12-30 Bengt Gustavsson Fluid transfer system
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CN1122456C (zh) * 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
EP1968551A2 (en) 2005-12-02 2008-09-17 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
JP6235779B2 (ja) * 2012-03-28 2017-11-22 株式会社コーセー 葉酸含有組成物及び葉酸の安定化方法
EP2799061A1 (en) * 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en) * 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
DK3668516T3 (da) 2017-08-16 2021-12-13 Merck Patent Gmbh Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
CN107892692A (zh) * 2017-12-28 2018-04-10 华东理工大学 (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用

Also Published As

Publication number Publication date
US20250360135A1 (en) 2025-11-27
EP4536187B1 (en) 2026-01-28
EP4536187A1 (en) 2025-04-16
KR20250022145A (ko) 2025-02-14
WO2023237484A1 (en) 2023-12-14
EP4536187C0 (en) 2026-01-28
EP4706775A2 (en) 2026-03-11
CA3258734A1 (en) 2023-12-14
CN119365186A (zh) 2025-01-24
JP2025518274A (ja) 2025-06-12
IL317395A (en) 2025-02-01

Similar Documents

Publication Publication Date Title
EP2991619B1 (en) Stable pharmaceutical composition containing folates
US20090325978A1 (en) Stable lyophilized preparation
US9301922B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
US20090221594A1 (en) Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate
EP4536187B1 (en) Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
US20250319022A1 (en) Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate
HK40124505A (en) Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
HK40124505B (en) Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
US20070276008A1 (en) Pharmaceutical formulation comprising glycine as a stabilizer
US20250319089A1 (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
EP1039905B1 (en) Pharmaceutical formulation comprising glycine as a stabilizer
BR112024025249B1 (pt) Composições liofilizadas compreendendo 5,10- metileno-(6r)-tetrahidrofolato dissódico, seu uso e seu processo de preparação, e produto reconstituído
US20260000671A1 (en) Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
US20200246263A1 (en) Stable liquid compositions of pemetrexed
CA3258607A1 (en) STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND NACL
WO2025165852A1 (en) Liquid formulations of lurbinectedin